CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays

Intro to Proteomics

Intro to Proteomics

This acquisition solidifies CellCarta’s leadership position in proteomics services with an unique mix of validated set of reagents and multiplex assays, consisting of path particular off-the-shelf panels, enabling for scientific protein metrology covering a detailed range of immuno-oncology targets.

MONTREAL, May 19, 2022/ PRNewswire/ CellCarta, a leading global company of accuracy medication laboratory services, announced today the acquisition of the business rights to the antibody panels and assays from Precision Assays, a leader in next-generation targeted proteomics checking services. A spin-off from Fred Hutchinson Cancer Center (” Fred Hutch”), Accuracy Assays develops and deploys high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for its biotech and pharmaceutical industry customers.

The acquisition from Precision Assays of its large spectrum of targeted mass spectrometry assays identified according to the National Cancer Institute’s Clinical Proteomic Growth Analysis Consortium (CPTAC) Tier 2 guidelines significantly expands CellCarta’s abilities in off-the-shelf multiplex protein quantification offerings prepared for deployment in immuno-oncology clinical and pre-clinical studies. Obtaining Accuracy Assays’ portfolio of verified assays reinforces CellCarta’s development method to end up being the leading service provider of accuracy medicine services and will enable the company to extend proteomics services from discovery to scientific settings.

Based on technology accredited from Fred Hutch, Accuracy Assays’ platform is uniquely positioned to fully record the unique benefits of multiplex protein quantification using targeted mass spectrometry. Accuracy Assays is one of the few CROs to provide immuno-oncology and large appropriate multiplex off-the-shelf panels and is at the forefront of targeted-mass spec proteomics-based research study.

“As an international CRO with competence in targeted mass spectrometry and focusing on biomarker screening to support accuracy medication, CellCarta is an ideal partner to release and industrialize our platform to support discovery, translational and scientific research, specifically in precision medicine and immuno-oncology”, Paulovich stated.
About CellCarta

READ  Proteomics International Laboratories' (ASX: PIQ) diabetic kidney illness tests ranked above current requirement of care

CellCarta is a leading company of specialized accuracy medicine lab services to the biopharmaceutical market. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as associated specimen collection and logistics services, CellCarta supports the entire drug advancement cycle, from discovery to late-stage medical trials. The company runs globally with 11 centers located in Canada, USA, Belgium, Australia, and China.

The acquisition from Precision Assays of its large spectrum of targeted mass spectrometry assays identified according to the National Cancer Institute’s Medical Proteomic Tumor Analysis Consortium (CPTAC) Tier 2 standards considerably broadens CellCarta’s capabilities in off-the-shelf multiplex protein metrology offerings ready for deployment in immuno-oncology scientific and pre-clinical studies. “Accuracy Assays’ big portfolio of robust assays characterized according to CPTAC guidelines and its established evidence of concept data will allow CellCarta to confidently support its clients’ exploratory studies and healing advancement methods, using them essential services to deal with crucial medical difficulties and move their immuno-oncology programs forward. Acquiring Accuracy Assays’ portfolio of confirmed assays reinforces CellCarta’s growth strategy to become the leading supplier of accuracy medicine services and will permit the organization to extend proteomics services from discovery to scientific settings.